Gyre Therapeutics Files Q1 2025 10-Q
Ticker: GYRE · Form: 10-Q · Filed: May 9, 2025 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | 10-Q |
| Filed Date | May 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
TL;DR
Gyre Therapeutics filed its Q1 2025 10-Q. Financials and business updates are in.
AI Summary
Gyre Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Catalyst BioSciences, Inc., reported financial results and business updates. Key financial data and operational details for the first quarter of 2025 are presented in this filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Gyre Therapeutics, crucial for understanding the company's trajectory and investment potential.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Gyre Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End (The 10-Q covers financial information up to this date.)
- 2025-05-09 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- GYRE THERAPEUTICS, INC. (company) — Filer
- CATALYST BIOSCIENCES, INC. (company) — Former Company Name
- TARGACEPT INC (company) — Former Company Name
- 20250331 (date) — Reporting Period End Date
- 20250509 (date) — Filing Date
FAQ
What were Gyre Therapeutics' primary business activities during the quarter ending March 31, 2025?
The filing indicates activities related to 'GyrePharmaceuticals' and 'MainlandChinaContributionPlan' during the period of January 1, 2024, to March 31, 2024, and potentially ongoing in 2025.
What is the company's former name, and when was it changed?
The company was formerly known as CATALYST BIOSCIENCES, INC., with a name change date of August 20, 2015. It was also formerly known as TARGACEPT INC, with a name change date of September 19, 2000.
What specific financial statement items are mentioned for the reporting period?
The filing references items such as 'GeneralAndAdministrativeExpense', 'CVRDerivativeLiability', 'FinanceReceivables', and 'CommonStock' as of March 31, 2025.
Are there any specific intellectual property rights mentioned in the filing?
Yes, 'NintedanibIPRights' are mentioned as of March 31, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding GYRE THERAPEUTICS, INC. (GYRE).